topotecan has been researched along with cabozantinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Scorsone, K; Woodfield, SE; Zage, PE; Zhang, L | 1 |
| Barbuti, AM; Chen, ZS; Wang, YJ; Wen, AW; Wurpel, JND; Yu, XY; Zhang, GN; Zhang, YK; Zhu, XJ | 1 |
3 other study(ies) available for topotecan and cabozantinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Immunocompromised Host; Inhibitory Concentration 50; Isotretinoin; MAP Kinase Signaling System; Mice; Neoplasm Proteins; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2015 |
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Topics: Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mitoxantrone; Molecular Docking Simulation; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan | 2017 |